NR2E3 and retinal degeneration: This was a pharmacological study to demonstrate the efficacy of dosage and longitudinal impact of NR2E3 modifier gene therapy to treat retinal degeneration in the RhoP23H+/− mouse when administered during early/intermediate degeneration.